|
KMID : 0338420170320061025
|
|
The Korean Journal of Internal Medicine
2017 Volume.32 No. 6 p.1025 ~ p.1036
|
|
|
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
|
|
Lee Hae-Young
Kim Cheol-Ho
Song Jae-Kwan
Chae Shung-Chull
Jeong Myung-Ho
Kim Dong-Soo
Oh Byung-Hee
|
|
|
Abstract
|
|
|
Background/Aims: Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in patients with mild to moderate hypertension.
Methods: This study was a phase II, prospective, multicenter, randomized, double-blind, parallel-grouped trial. A total of 75 hypertensive patients, whose mean ambulatory BP monitoring values were ≥ 135/85 mmHg, were randomized to either fimasartan 30 mg or valsartan 80 mg daily. The primary efficacy endpoint was the change in the mean 24-hour systolic BP (SBP) values from the baseline and at the week 8. Secondary endpoints included the change in the mean 24-hour diastolic BP values, the daytime and the nighttime mean BP values at week 8, the trough-to-peak (T/P) ratio and the smoothness index.
Results: At week 8, the mean 24-hour SBP values significantly decreased in both groups; ?10.5 ± 11.9 mmHg (p < 0.0001) in the fimasartan group and ?5.5 ± 11.6 mmHg (p = 0.0307) in the valsartan group. The difference between two groups was 4.3 ± 2.9 mmHg but there was no statistical significance (p = 0.1392). The global T/P ratio in the fimasartan 30 mg groups were 0.48 and 0.40 in the valsartan 80 mg group, respectively (p = 0.3411). The most frequent adverse events (AEs) were acute pharyngitis and there were no cases of severe AEs.
Conclusions: In mild-to-moderate hypertensive patients, low dose (30 mg) fimasartan showed comparable 24-hour BP lowering efficacy compared with valsartan (80 mg). There was no difference in tolerability between two groups.
|
|
|
KEYWORD
|
|
|
Hypertension, Angiotensin II type 1 receptor blockers, Blood pressure monitoring, ambulatory
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|